 By John Vandermosten, CFA NASDAQ:AZRX On July 20, 2020, AzurRx NASDAQ: AZRX announced the closing of 15.2 million in a private placement and repayment of 6.9 million in convertible notes. The proceeds in excess of the liability repayment will be used to advance the two Phase II clinical trials of MS1819 in patients with cystic fibrosis. The company issued 2,912 shares of Series B Convertible 